Parkinson's disease is a chronic progressive neurodegenerative disorder that primarily affects the dopamine neurons in the central nervous system. This disease typically begins after the age of 50, although there are a few reports of early-onset cases. The core symptoms include bradykinesia, tremors, and muscle rigidity, which gradually worsen and severely impact daily life. Currently, there is no cure, but medications, surgery, and rehabilitation therapies can effectively alleviate symptoms and slow disease progression.
Globally, approximately 100-160 individuals per 100,000 are affected by this disease, with a slightly higher prevalence in men than in women. Although the exact cause is not fully understood, research indicates that it is related to genetic factors, environmental exposures, and a reduction in dopamine neurotransmitters in the brain. Recent clinical studies have found that non-motor symptoms such as loss of smell and sleep disorders may exist years before the onset of motor symptoms, providing new directions for early diagnosis.
The exact cause of Parkinson's disease requires more research, but existing evidence suggests it results from the interaction of genetic and environmental factors. The gradual death of dopamine neurons in the substantia nigra is a primary pathological feature, leading to an imbalance in neurotransmission in the basal ganglia. Genetic mutations such as SNCA and LRRK2 increase the risk of developing the disease, with about 10-15% of patients having a family history.
Gene mutations such as PARK7 and PINK1 are associated with mitochondrial dysfunction, leading to impaired autophagy in nerve cells. Recent genome-wide studies have found that polygenic polymorphisms can increase the likelihood of developing the disease, but single gene mutations account for only about 5% of cases. Familial forms of the disease often present with early-onset non-motor symptoms.
Symptoms can be categorized into motor and non-motor symptoms, with early stages often characterized by unilateral limb involvement. The development of motor impairments typically follows the "three cardinal signs": resting tremor, rigidity, and bradykinesia. Non-motor symptoms such as loss of smell and sleep behavior disorders may appear 5-10 years before significant motor symptoms.
Typical motor symptoms include:
Non-motor symptoms encompass a wide range, including autonomic dysfunction (such as blood pressure fluctuations), cognitive impairments (from mild cognitive impairment to Parkinson's dementia), emotional issues (depression and anxiety symptoms), and sleep disorders (REM sleep behavior disorder). These non-motor symptoms may be underestimated and require detailed assessment for comprehensive understanding of the condition.
Diagnosis primarily relies on clinical evaluation, as there is currently no single biomarker that can confirm the diagnosis. Neurologists will make a diagnosis through detailed medical history collection, assessment of motor function, and exclusion of other similar diseases. The diagnostic process typically includes dynamic tests (such as olfactory tests), imaging studies (such as PET scans), and analysis of symptom progression.
It is necessary to differentiate from primary tremor, multiple system atrophy, and progressive supranuclear palsy. For example, patients with primary tremor do not exhibit muscle rigidity, while multiple system atrophy is often accompanied by autonomic dysfunction. The accuracy of diagnosis may be lower in the early stages, requiring monitoring of symptom changes.
Positron emission tomography (PET) can detect changes in the brain's dopamine pathways, and serum biomarkers such as alpha-synuclein testing are still in the validation phase. The Unified Parkinson's Disease Rating Scale (UPDRS) is commonly used in clinical settings to quantify the severity of symptoms.
The goal of treatment is to improve quality of life and slow disease progression, with treatment strategies adjusted based on the patient's age, severity of symptoms, and comorbid conditions. Pharmacological treatment primarily aims to supplement dopamine system function, while surgical therapies provide alternatives for specific patients.
The gold standard medication is Levodopa, which converts to dopamine after crossing the blood-brain barrier; however, long-term use may lead to dyskinesia as a side effect. Adjunct medications include dopamine agonists (such as pramipexole) and monoamine oxidase B inhibitors (such as rasagiline), which can slow symptom deterioration.
Deep Brain Stimulation (DBS) is effective for moderate patients with fluctuations in medication response, with common target sites being the subthalamic nucleus and the internal segment of the globus pallidus. This surgery requires strict evaluation of the patient's medication response curve and psychological state, and post-surgery, medication adjustments are still necessary.
Physical therapy improves mobility impairments through balance training and gait training, while speech therapy can alleviate speech reduction issues. Recent studies have shown that dance therapy and Tai Chi significantly improve motor agility.
Currently, there is no evidence that specific measures can completely prevent Parkinson's disease, but the following lifestyle adjustments may reduce risk:
If any of the following symptoms occur, seek medical attention promptly:
When symptoms such as bradykinesia, rigidity, or tremors worsen again, or daily activity ability declines, it may indicate reduced medication effectiveness. It is advisable to record the timing of symptom changes and their correlation with peak medication effects, and discuss dosage adjustments or treatment plans with your doctor, avoiding self-modification of medication.
What daily exercises can help improve the mobility of Parkinson's patients?Balance training such as Tai Chi, water exercises, or dance can effectively strengthen muscle control and coordination. It is recommended to engage in at least 150 minutes of moderate-intensity exercise per week, preferably under the guidance of a therapist, to slow the progression of motor impairments.
Are there specific nutrients or dietary practices that can delay the progression of Parkinson's disease?Currently, there is no specific diet that can treat this disease, but high-fiber, antioxidant-rich foods (such as dark vegetables and berries) may help reduce oxidative stress. Maintaining an adequate protein intake and distributing it throughout meals can enhance the absorption efficiency of Levodopa.
When should surgical treatment be considered? Do the risks and effects vary from person to person?When medications cannot stabilize symptoms and severely impact daily life, Deep Brain Stimulation (DBS) may be an option. The effects vary from person to person, with about 70% of patients experiencing a 30-50% improvement in tremors and motor impairments, but cognitive function and surgical risks, such as infection or device failure, must be assessed.
How can non-motor symptoms such as anxiety or depression commonly encountered by patients be effectively managed?Psychotherapy (such as cognitive-behavioral therapy) and antidepressant medications can alleviate emotional issues, but monitoring for side effects by a psychiatrist is necessary. Joining support groups and regularly communicating with family about changes in the condition can also enhance psychological adaptability and reduce feelings of social isolation.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
